PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gilles Salles(Memorial Sloan Kettering Cancer Center), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Wayne R. Godfrey(Dana-Farber Cancer Institute), Peter Martin(Northwestern University), Roger Dansey(Memorial Sloan Kettering Cancer Center), Martin Dreyling(LMU Klinikum), Kristie A. Blum(Emory University), Andreas Viardot(University Hospital Ulm), Brad S. Kahl(UW Health University Hospital), Andrew Davies(University Hospital Southampton NHS Foundation Trust), Stephen J. Schuster(Hospital of the University of Pennsylvania), Sven de Vos(University of California, Los Angeles), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Daniel Li(Memorial Sloan Kettering Cancer Center), Wojciech Jurczak(Jagiellonian University), Dave Johnson, Ian W. Flinn(Tennessee Oncology), Langdon L. Miller(Gilead Sciences (United States)), Leanne Holes(Gilead Sciences (United States))
Cited by 1,062
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k